Aim: Compound 1-(4-chlorophenyl)-4,4,4-trifluoro-3-hydroxy-2-buten-1-one (compound 1) was identified as a hit against methicillin-resistant Staphylococcus aureus (MRSA) strain MW2.
Introduction
Intracellular killing assays. RAW 264.7 macrophages were used to evaluate intracellular Bacterial membrane permeabilization assays. Sytox green (Life Technologies, Carlsbad, CA, 124 USA) (a nucleic acid stain not permeable to intact membrane) was used to measure membrane 125 permeabilization by test compounds, as previously described [24] . Assays were carried out in 126 duplicate in 96-well plates (Corning, Corning, NY, USA) using MRSA-MW2. Bacteria were 127 harvested from logarithmically growing cultures by centrifugation at 3724 x g for 5 minutes, concentration, aliquots were used to dilute into fresh medium to inoculate the second set of serial 138 drug dilutions as described by Dalhoff et al., [25] . After overnight incubation, bacteria were 139 passaged sequentially for a period of 25 days.
140
Human red blood cell hemolysis. Human erythrocytes (Rockland Immunochemicals, Limerick, 141 PA, USA) were used to test the hemolytic properties of compound 1, as detailed in reference 142 [26] . Briefly, 50 µL of 4% human erythrocytes suspended in PBS were added to 50 µL of test 143 compound that had been serially diluted in PBS in 96 well plates. After incubating at 37°C for 1 transferred to a second 96-well plate. Visual inspection and absorbance at 540 nm were used to 146 measure hemolysis.
147
Mammalian cell cytotoxicity assays. HepG2 cells were used to probe mammalian cell 148 cytotoxicity of compound 1, as described by Kwon et al., [27] cells/mL, as determined by optical density at 600 nm, before inoculation into G. mellonella 188 larvae. A 10 µL inoculum was injected into the last left proleg using a 10 µL Hamilton syringe.
189
Compounds were administered at 25 µg/mL into the last right proleg before (prophylactic) or 2 h after (therapeutic) inoculation and the moths incubated at 37°C. Three groups were used as 4x MIC (16 µg/mL), MRSA-MW2 cell CFU/mL counts were reduced by 1-log 10 compared to 217 the initial inoculum (Figure 2A) , demonstrating that the compound is bacteriostatic. (Figure 3C ). At pH 6.0 the MIC of compound 1 was reduced 4-fold to 1 µg/mL 235 and at pH 5.0 an 8-fold decrease was observed (MIC = 0.5 µg/mL) ( Figure 3A-B) . In contrast, Figure 6C ).
297

Conclusion
298
In summary, compound 1 shows bacteriostatic activity against MRSA that is enhanced at 
Future perspective
306
MRSA is categorized as a "serious threat" by the Centers for Disease Control and Prevention
307
(CDC) and is associated with ≥11,000 deaths per year. Our study demonstrates that the 
316
• The compound is bacteriostatic.
317
• Importantly, the efficiency of the compound was increased in acidic pH and the MIC was 318 reduced by 4-fold (to 1 µg/ml) in pH 6.0 and by 8-fold (to 0.5 µg/ml) in pH 5.0.
319
• Treatment with the compound resulted in a 1-log 10 reduction of CFU/mL of intracellular
320
MRSA-MW2 bacteria.
321
• We confirmed the activity of the compound using two alternative model hosts: 
326
• Notably, administration of compound resulted in a reduced intracellular pH (6.5) of 327 MRSA-MW2 by dissipating the proton gradient and concentrations up-to 64 µg/ml did 328 not cause toxicity to human red blood cells.
329
• This potential protonophore warrants further evaluation for the development of this 330 compound as a novel antibacterial agent. 
